Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of SY-008 in Healthy Chinese Subjects
NCT03462589Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SY-008 in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 at 7 days. Started Aug 2018; status: completed.
02
Drugs
SY-008
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03462589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462589.